Mass. Pike lane closures in Newton, Weston to cause heavy delays. Here's what you need to know
The closures on I-90 will be between exits 123 and 125 in Weston and Newton, a two-mile stretch from the Ridgeway Road bridge in Weston to the Commonwealth Avenue overpass in Newton.
MassDOT is reducing traffic to one lane in each direction until Monday at 5 a.m.
'They'll be demolishing the roof of that existing tunnel and then replacing it with prefabricated bridge unit. This will be happening over the next couple of days,' Highway Administrator Jonathan Gulliver said.
Peak traffic could cause up to three hours of delays and officials strongly advise drivers to avoid the area if possible.
The project is also temporarily shutting down the commuter rail this weekend.
'They'll be on shuttle buses, that's both Amtrak and the MBTA out from as far as Worcester, if you're coming in, you're going to be on a shuttle bus; they have their own detour routes that they'll be using throughout the weekend,' Gulliver said.
Phase two of the project will be the weekend of June 20th. buses.
MassDOT says they are working with state and local law enforcement. Drivers are encouraged to make extra time, but also, most importantly, slow down.
This is a developing story. Check back for updates as more information becomes available.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 hours ago
- Associated Press
Gigatrends, AI, and the Future of Oncology Clinical Pathways to Take Center Stage at HMP Global's CPC+CBEx 2025
Renowned futurist and Delphi Group Chairman & Founder Thomas Koulopoulos to deliver keynote at national event held September 5-6 in Boston. 'The next wave of healthcare won't reward those who build bigger hospitals or prettier dashboards—it will reward those who turn clinical pathways into adaptive, learning ecosystems.'— Thomas Koulopoulos, Delphi Group Founder & Chairman MALVERN, PA, UNITED STATES, August 15, 2025 / / -- Against a backdrop of rapid innovation and mounting complexity in oncology, the 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) will convene September 5–6 in Boston, Massachusetts. The event will bring together cancer care leaders, payers, and innovators to examine how major trends—artificial intelligence, emerging treatments, stakeholder collaboration, whole-person care, and workforce transformation—are reshaping the design and implementation of clinical pathways and value-based care strategies. Keynote speaker Thomas Koulopoulos will deliver keynote remarks, 'Navigating Tomorrow's Healthcare Gigatrends,' from 9:25 – 10:10 AM on September 5, exploring how healthcare organizations can evolve legacy models into adaptive, AI-supported systems. Koulopoulos is Chairman and Founder of Delphi Group, a 30-year-old Boston think tank named one of the fastest growing private companies by Inc. Magazine, a renowned author and inventor, and the founding partner of Acrovantage Ventures, which invests in early-stage technology startups. What is Clinical Pathways Congress + Cancer Care Business Exchange? The Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) is a national conference focused on the design, implementation, and evolution of oncology clinical pathways. The event brings together leaders across cancer care, policy, pharmaceutical innovation, and health systems to accelerate value-based care strategies, healthcare infrastructure solutions, and market access innovations that redefine oncology. 2025 Educational Program Highlights • AI-Enabled Pathways: Explore how artificial intelligence, real-time data, and digital tools are transforming pathway design and clinical decision-making in oncology. • Value-Based Oncology Care: Learn how evolving CMS policies and payment models are reframing cancer care economics—and how pathways can serve as strategic levers for value creation. • Collaborative Leadership: Attend panel sessions featuring oncologists, pharmacists, data scientists, health system executives, and policy advocates working to align clinical, operational, and financial priorities. • Real-World Tools for Implementation: Gain access to practical implementation toolkits and strategies showcased through high-impact, peer-reviewed programming—offering actionable insights to support frontline adoption of clinical pathways and drive measurable outcomes. Key Benefits of Attending • Understand how top cancer organizations combat staffing strain and burnout by leveraging AI, expanding roles, and building resilient models. • Join providers, payers, and pathway developers as they collaborate to accelerate pathway adoption and deliver optimal access assistance. • Gain insider perspectives from pathway developers and clinical leaders on how pharma can meaningfully engage to shape inclusion decisions. • Participate in curated B2B networking through the Cancer Care Business Exchange (CBEx). • Earn CME/CE credits while gaining practical, system-wide strategies. Thomas Koulopoulos on Gigatrends and the Future of Oncology • How AI and virtual health can create a continuous care loop: 'AI's pattern-recognition and virtual health's 'anywhere, anytime' reach fuse into a continuous care loop ... The prize: fewer cliff-edge hospitalizations and a seamless hand-off from prevention to acute to chronic management.' • Why clinical pathways are the lever for value over cost: 'When pathways are built around outcomes instead of encounters, they become the financial Rosetta Stone that translates 'spend' into 'health value.'' • The future of care systems: 'The next wave of healthcare won't reward those who build bigger hospitals or prettier dashboards—it will reward those who turn clinical pathways into adaptive, learning ecosystems.' Who Should Attend • Cancer center executives, innovation directors, and service line directors • Oncology operations and quality leaders • Pathway implementation managers and VBC strategists • Health economists, outcomes researchers, and market access teams • Consultants and digital health innovators Event details • Event: Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) • Dates: September 5–6, 2025 • Location: Boston, Massachusetts • Event Website About HMP Global HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit Sandi Beason, APR HMP Global [email protected] Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
21 hours ago
- Yahoo
Reprieve Cardiovascular raises $61M; Conformal Medical nets $32M for LAAO
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Reprieve Cardiovascular said Wednesday it closed a $61 million Series B financing that will fund its pivotal clinical trial and preparations to commercialize its heart failure fluid management system. The Milford, Massachusetts-based company is developing a system for removing excess fluid in patients with acute decompensated heart failure. The goal is to personalize decongestion management by removing fluid and sodium through precise administration of diuretics. "Reprieve Cardiovascular is addressing a significant unmet need in today's heart failure management paradigm,' Anita Watkins, managing director of Rex Health Ventures, said in a statement. Rex Health is the corporate venture fund of UNC Health and a Reprieve investor. CEO Mark Pacyna said the funding will help Reprieve generate the clinical and economic evidence needed to pursue regulatory approval and commercialization of the system. He said the company believes its approach to decongestion management can lead to better outcomes for both patients and healthcare systems. The randomized pivotal FASTR II trial will compare the Reprieve system to optimal diuretic therapy in patients hospitalized with ADHF to assess whether the device can decongest patients more effectively than the standard of care. The study plans to enroll up to 400 patients across the U.S. and Europe and will be used to support a Food and Drug Administration premarket approval submission. The first patient has been enrolled by a team at the Washington University School of Medicine in St. Louis. The FASTR II trial follows the completion late last year of the FASTR randomized pilot study, which met its primary efficacy and safety endpoints. The company's oversubscribed Series B round was led by Deerfield Management. Along with Rex Health, other backers were Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Cadence Capital and an undisclosed strategic investor. The financing combined equity investment with a debt facility. Reprieve's Series A financing raised $42 million in 2024. Conformal aims to advance left atrial appendage occlusion Conformal Medical said Tuesday it raised $32 million in a Series D extension round to fund an ongoing pivotal trial and pre-commercialization work for its left atrial appendage occlusion system. The device, called CLAAS AcuFORM, is designed to seal the left atrial appendage in patients with atrial fibrillation not caused by a heart valve problem, to reduce the risk of stroke without long-term anticoagulants. The foam-based architecture is intended to work in a broad range of LAA anatomies with just two sizes. The company said its technology could make left atrial appendage closure a same-day, single-operator procedure and eliminate the need for general anesthesia and intubation. The CONFORM pivotal trial is evaluating the safety and efficacy of the system compared to other commercially available LAAO devices and will be used to support FDA pre-market approval, the company said in the funding announcement. The study, which is expected to randomize about 1,600 patients at sites worldwide, is now more than 30% enrolled. Nashua, New Hampshire-based Conformal said a new partner joined inside investors in the latest funding round. Recommended Reading SetPoint Medical secures $140M to fund neuromodulation for arthritis Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
a day ago
- Medscape
Early Diagnosis and Treatment of Alzheimer's Disease
Alzheimer's disease (AD) is a progressive disease in which subtle symptoms of dementia gradually worsen over time. Clinicians are now encouraged to diagnose AD in early stages; not only can early treatment slow disease progression, but nearly 80% of Americans want to know whether they have AD before symptoms interfere with daily activities. In this panel ReCAP, Dr Michael Rafii, of University of Southern California, Los Angeles; and Dr Salvatore Napoli, of Neurology Center of New England, Foxborough, Massachusetts, discuss how early diagnosis of AD is essential because new disease-modifying therapies are most effective in early-stage AD. They explain that effective assessment begins with a structured clinical interview and neurologic exam, followed by a brief cognitive screening. If these results suggest mild cognitive impairment, further steps include a baseline brain MRI to rule out other causes. The experts discuss how advancements in Alzheimer's disease treatment have highlighted the importance of confirming amyloid buildup as a prerequisite for initiating certain therapies. Specifically, antiamyloid monoclonal antibody infusions, such as bimonthly lecanemab and monthly donanemab, require biomarker evidence of amyloid pathology in patients with early AD. Finally, the panelists emphasize the importance of real-world data collection, highlighted by ALZ-NET, a national registry designed to gather clinical, imaging, and safety data from patients with memory concerns or those receiving new AD therapies.
